Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

BackgroundNeoadjuvant therapy, which aims to achieve a pathological complete response (pCR) for better overall survival (OS) has several advantages for patients with early breast cancer (eBC) and subtypes of HER2-positive (HER2+) and triple-negative breast cancer (TNBC). However, there has been no l...

Full description

Bibliographic Details
Main Authors:	Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, Huang-Tz Ou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	early breast cancer HER2-positive breast cancer triple-negative breast cancer trastuzumab platinum neoadjuvant therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1022994/full

Similar Items

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
by: Xavier Pivot, et al.
Published: (2023-01-01)

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
by: Qiyun Shi, et al.
Published: (2023-12-01)

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
by: MA Xiangmin, et al.
Published: (2022-01-01)

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
by: Yi Xiao, et al.
Published: (2022-05-01)

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
by: Azzurra Irelli, et al.
Published: (2022-06-01)

Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
by: Xueying Wu, et al.
Published: (2022-01-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
by: Chau Dang, et al.
Published: (2022-05-01)

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
by: Gavin P. Dowling, et al.
Published: (2024-01-01)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
by: Phung HT, et al.
Published: (2020-10-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study
by: Jing Peng, et al.
Published: (2024-03-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
by: Haoqi Wang, et al.
Published: (2022-07-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
by: Sarita Shrivastva, et al.
Published: (2023-07-01)

A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer
by: Shiwen Huo, et al.
Published: (2024-03-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
by: Lun Li, et al.
Published: (2021-07-01)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
by: Zhou Qiong, et al.
Published: (2020-07-01)

Trastuzumab administration during pregnancy: un update
by: Angeliki Andrikopoulou, et al.
Published: (2021-04-01)

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
by: Charlie Yang, et al.
Published: (2022-06-01)

Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer
by: V. A. Kostorov, et al.
Published: (2018-07-01)

Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report
by: Guoping Chen, et al.
Published: (2022-12-01)

Cardiotoxicity Associated with Trastuzumab Therapy in Taiwan: A Single Medical Center's 5-Year Experience
by: Che-Ming Chang, et al.
Published: (2015-06-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
by: Guang-Yi Sun, et al.
Published: (2021-01-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01)